Neu Direction: Testing the Efficacy of Adding HER Inhibition to Standard of Care in Metastatic MLH1-low Endocrine-resistant ER+/HER2- Breast Cancer

Clinical trial NCT07729046 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07729046
Sponsor: University of California, San Diego
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Metastatic Invasive Breast Cancer Resistant Breast Cancer ER+, HER2-, Metastatic Breast Cancer

Start date: 2027-07-01
Primary completion: 2032-05-01
Enrollment: 150

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.